Real-time triggers unlock precision in rare disease marketing
A paradox has emerged for life science leaders: As specialty and rare disease therapeutics dominate FDA approvals, their limited patient populations make it incredibly difficult to pinpoint eligible patients and their treating physicians for brands to drive adoption effectively. Traditional, broad-reach pharma marketing tactics are inefficient and have become a costly liability.
But a new opportunity for you to achieve disproportionate impact has emerged. The solution is to be precisely where and when it matters most—a paradigm shift enabled by trigger-based, hyper-personalized media.
This post will touch on challenges in rare disease HCP and patient identification and explore how an optichannel strategy, fueled by real-time, real-world data, is your key to accelerating access, adoption, and improved outcomes. It will empower you to make data-driven decisions on where and how to allocate resources for personalized and meaningful engagement, building disease state and product awareness over time and reaching HCPs precisely when they have an eligible patient.
The challenge: Disconnects and a narrow window of opportunity
The diagnosis-to-treatment window can be narrow in rare diseases, made more complex as patients usually spent years struggling to get diagnosed correctly.
Traditional data sources fall short here. HCP affinity (preference and behavior) data is often assessed only once during campaign tactical planning. For targeting, marketers have relied on historical EHR and claims data—information that can be delayed by months and is often unreliable due to diagnostic complexity. These create disconnection, placing broad reach campaigns far beyond the weeks-long timeframe when treatment decisions are being made.
This is compounded by HCP knowledge gaps. Most physicians are generally unfamiliar with a specific rare disease, let alone the treatment options. A marketing strategy must therefore address a three-fold challenge:
- Efficiently identifying the right providers with eligible patients
- Simultaneously providing the credible, scientific information they need to act with confidence
- Getting it to them fast enough to inform rapid decision-making.
The solution: From passive data to proactive triggers
How can you overcome these barriers? Pivot from passive, historical data to a proactive, real-time trigger model.
Instead of reacting to what happened months ago, act based on what's happening right now: real-world data points that offer the earliest and most valuable signals of a patient or an HCP journey. This versatile solution reaches far beyond just ICD-10 code diagnoses (if they even exist).
Lab data, for instance, is often the most real-time information a physician receives regarding a potential diagnosis. By leveraging this as a primary trigger when available, a campaign can initiate engagement with an HCP within 24-48 hours of a test order or result, putting your message in their hands precisely when they are considering treatment options.
Optichannel strategies go beyond any single real-world data source. It’s key to leverage multiple signals to identify the optimal channel mix and create a holistic, dynamic picture of a provider’s behavior and their patient’s journey. This also offers alternatives when lab testing or awareness is low or non-existent. Other script, diagnostic procedure, or infusion claims data could be used, for example.
Other triggers might include predictive models. Advanced analytics solutions may anticipate when a patient is highly probably to progress or switch for disease management over time, or use symptomatic identifiers or routine monitoring schedules to predict new diagnoses and enable timely, proactive outreach.
Behavioral signals can also be leveraged. Digital behaviors, such as online search queries, event attendance, publication download, or even competitor research monitoring (if relevant), pinpoint when a provider is seeking relevant information and indicate a moment of high intent.
We know for a small company or team, this level of coordination can sound daunting. The good news is that this model is a game-changer for a small commercial team.
Many rare disease brands have lean sales teams covering large territories, making it impossible to cover every potential prescriber. Triggers uncover non-list HCPs with eligible patients across the care team, pulling them into campaigns and flagging them for sales outreach (or continued digital engagement if they are no- or low-see). This extends your reach beyond traditional, static target list media models, ensuring no critical opportunities are missed.
The tactical execution: How optichannel delivers
What does this model look like in practice? The foundation is a platform that can seamlessly ingest real-time data from multiple sources—such as labs, EHRs, medical and script claims vendors—for clinical signals to achieve high data coverage as well as real-time digital and event behavior tracking—like congress information, search behavior, engagement in always-on or DSE campaigns, and move—that build a holistic view of the patient and provider journey.
Next, create journeys and automate orchestration. Once a trigger is detected, the platform automatically deploys hyper-personalized content, removing the manual, time-intensive processes that cause critical delays in traditional campaigns.
Personalization happens essentially simultaneously–the system determines the optimal channel for each message, ensuring the content is delivered via the HCP’s preferred medium and vendor (e.g., email, social, field syncs, EHR banners). This avoids media fatigue and increases the chance of meaningful interactions.
Optimization comes next. This happens at an individual NPI level, as machine learning updates journeys over time based on engagement data (or non-engagement), and at the campaign level. NPI-level tracking of new scripts makes it clear exactly what tactics are driving adoption and where investments should pivot if they aren’t having the expected impact.
This data-driven approach ensures your educational content and messaging reach the right audience precisely when they need it. Results are tracked transparently, allowing resource reallocation far more quickly than the quarterly, half-year, or even annual model in traditional media buying cycles.
Case study: A real-world example
Here’s how our trigger-based optichannel campaign drove outsized impact for a brand team looking to supercharge a lackluster launch campaign. The team needed to establish share of voice and market share among two specialties. There were approved and off-label competitors, and no clear treatment guidelines were established.
Multiple mutation lab and claims triggers identified critical moments of diagnosis rapidly. We supplemented this with a predictive model to identify when a patient on therapy will be eligible to switch, plus symptomatic identifiers and 6-month MRI schedules to trigger each HCP with personalized messaging. This deployed via automated next-best-action journeys on the channels most likely to engage target ophthalmologists and neurologists across endemic display, email, Veeva, and custom media.
Harnessing real-world data, our optichannel campaign increased engagement and Rx lift within 6 months. This campaign:
- More than doubled HCP engagement rates (from 14% to 32%) compared to the prior DSE campaign
- Grew NRx market share per month from 28% to 45%
- Identified over 1,000 additional non-list HCPs for engagement
- Delivered about 13,000 brand touchpoints to target list and additional HCP
This data-driven approach proves that even in an unusually crowded rare indication, a lean team can not only compete but outperform.
The ROI of precision
The goal of this shift is to improve engagement and drive meaningful business outcomes. By connecting a campaign’s digital exposure directly to Rx lift and revenue, a trigger-based model provides the transparent, measurable ROI that rare disease marketing and commercial leaders need to justify their investments.
In the case study above, this model drove 17% Rx lift, with 70% of scripts tracked back to PFIQ triggers. In a separate ultra-rare indication, our trigger-based, hyper-targeted campaign drove a 27% increase in market share and more than tripled HCP engagement rates within 1 year—while delivering 47% media savings compared to their previous campaign.
These numbers are a testament to the power and efficiency of a strategic, data-driven approach to rare disease marketing, even for a lean team.
The optichannel path forward
Optichannel marketing is the future of rare disease commercialization. It replaces guesswork with data, lags with speed, and inefficiency with tangible ROI. By leveraging precision, real-time data, and agile execution, your team can move past the limitations of traditional pharma marketing models and empower your commercial engine to reach the right patients and providers rapidly.
Ready to see how to implement this model for transparent ROI? Let’s connect. We can help you launch a hyper-targeted pilot in as little as 6-8 weeks, getting you results that will speak for themselves.